Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b: Adverse Effects
Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a lower risk of serious adverse events (2 trials; pooled relative risk [RR], 0.74; 95-percent confidence interval [95% CI], 0.57 to 0.95), neutropenia (5 trials; pooled RR, 0.60; 95% CI, 0.46 to 0.83), and rash (2 trials; pooled RR, 0.79; 95% CI, 0.71 to 0.88) than with dual therapy with pegylated interferon alfa-2a plus ribavirin. There were no differences in withdrawals due to adverse events.
Keywords: finding | outcome | hepatitis C | HCV | treatment | dual therapy | adverse effects | strength of evidence
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.